Biopharma company Jazz Pharmaceuticals (NASDAQ: JAZZ) fell short of the market’s revenue expectations in Q1 CY2025, with sales flat year on year at $897.8 million. On the other hand, the company’s outlook for the full year was close to analysts’ estimates with revenue guided to $4.28 billion at the midpoint. Its non-GAAP profit of $1.68 per share was 63.9% below analysts’ consensus estimates.
Is now the time to buy JAZZ? Find out in our full research report (it’s free).
Jazz Pharmaceuticals (JAZZ) Q1 CY2025 Highlights:
- Revenue: $897.8 million vs analyst estimates of $986.6 million (flat year on year, 9% miss)
- Adjusted EPS: $1.68 vs analyst expectations of $4.66 (63.9% miss)
- Adjusted EBITDA: $206.5 million vs analyst estimates of $399.6 million (23% margin, 48.3% miss)
- The company reconfirmed its revenue guidance for the full year of $4.28 billion at the midpoint
- Management lowered its full-year Adjusted EPS guidance to $4.80 at the midpoint, a 79.4% decrease
- Operating Margin: -6.2%, down from 7.3% in the same quarter last year
- Free Cash Flow Margin: 46.3%, up from 28.9% in the same quarter last year
- Market Capitalization: $6.72 billion
StockStory’s Take
Jazz Pharmaceuticals’ first quarter results reflected a flat revenue performance and significant shortfall on non-GAAP earnings relative to Wall Street expectations. Management attributed this outcome primarily to strong demand in the neuroscience portfolio, particularly Xywav and Epidiolex, which offset near-term headwinds in oncology products such as Rylaze and Zepzelca. CEO Bruce Cozadd highlighted execution on commercial efforts, stating the company remains “confident in the blockbuster potential” of Epidiolex and is seeing “continued momentum” for Xywav, especially in idiopathic hypersomnia.
For the remainder of the year, management’s guidance is anchored by anticipated regulatory milestones and commercial launches in oncology. The company’s strategy includes leveraging recent acquisitions, such as Chimerix, to expand its rare oncology presence and prepare for upcoming product launches like Dordaviprone. Management also addressed ongoing litigation settlements and tariff risks, noting that inventory planning and flexible manufacturing are expected to minimize impacts for 2025.
Key Insights from Management’s Remarks
Jazz Pharmaceuticals’ Q1 performance was shaped by mixed trends across its portfolio, with neuroscience products showing growth and oncology products experiencing headwinds. Several strategic actions—including a major acquisition and regulatory filings—also influenced the quarter’s results and future positioning.
-
Neuroscience Portfolio Growth: Xywav and Epidiolex led revenue growth, with Xywav patient additions driven by targeted disease education campaigns and Epidiolex benefiting from expanded use in adult and long-term care settings. Management emphasized Xywav’s status as the only FDA-approved therapy for idiopathic hypersomnia, supporting market expansion.
-
Oncology Pressure and Pipeline: The oncology portfolio saw declines, primarily due to protocol changes affecting Rylaze and competitive dynamics for Zepzelca. Management expects normalization of Rylaze revenue and highlighted upcoming data presentations for Zepzelca’s first-line use, which could shift its growth trajectory if included in treatment guidelines.
-
Chimerix Acquisition and Dordaviprone Launch: The acquisition of Chimerix added Dordaviprone, a therapy for rare brain tumors, to the pipeline. Management described Dordaviprone as a "meaningful and durable revenue opportunity" due to its potential frontline use and patent protection into 2037.
-
Supply Chain and Tariff Preparedness: Jazz outlined its extensive manufacturing footprint in the U.S. and Europe, noting that diversified supply and inventory management should mitigate the impact of enacted and potential tariffs for the rest of the year.
-
Strategic R&D Progress: Multiple regulatory milestones are on the horizon, including FDA and European reviews for new oncology indications. Upcoming data from pivotal trials in HER2-positive cancers and the anticipated launch of Dordaviprone are expected to be key product catalysts.
Drivers of Future Performance
Looking ahead, Jazz’s guidance relies on continued neuroscience portfolio growth and the successful advancement of its oncology pipeline, while also navigating cost pressures and regulatory developments.
-
Oncology Regulatory Milestones: Management believes that data readouts and regulatory decisions for products like Dordaviprone and zanidatamab will be critical to expanding the oncology business and supporting revenue growth.
-
Neuroscience Market Expansion: The company expects further demand for Xywav, especially in idiopathic hypersomnia, to drive patient growth, while Epidiolex is positioned to achieve blockbuster status through expanded indications and access initiatives.
-
Tariff and Litigation Risks: While management downplayed tariff impacts for 2025 due to inventory and manufacturing flexibility, future regulatory changes or litigation expenses remain uncertainties that could affect margins and adjusted earnings.
Top Analyst Questions
-
Jason Gerberry (Bank of America): Asked about Xywav’s supply chain resilience if tariffs escalate, with management confirming U.S. manufacturing capacity can supply the domestic market and minimize tariff risk.
-
Jessica Fye (JP Morgan): Inquired about Jazz’s overall manufacturing footprint and contingency plans for biopharma tariffs, with management highlighting geographic diversification and a strategy of building U.S. inventory.
-
David Amsellem (Piper Sandler): Questioned the long-term outlook for Zepzelca in the face of new competition, with executives citing upcoming first-line data as potentially expanding its patient base and duration of therapy.
-
Annabel Samimy (Stifel): Sought updates on Rylaze’s adoption in adolescent and young adult segments, with management acknowledging slow but steady momentum and confidence in normalization by next quarter.
-
Joseph Thome (TD Cowen): Asked about Dordaviprone’s Phase III trial status and regulatory review, with Jazz noting ongoing enrollment outside the U.S. and no current issues with the FDA review timeline.
Catalysts in Upcoming Quarters
In the coming quarters, the StockStory team will watch for (1) pivotal data releases for zanidatamab in HER2-positive gastroesophageal cancer, (2) the FDA’s decision on Dordaviprone and progress in its confirmatory frontline trial, and (3) signs of sustained growth in Xywav and Epidiolex patient populations. Successful integration of Chimerix and the impact of evolving tariff policies will also be important to monitor as the year progresses.
Jazz Pharmaceuticals currently trades at a forward P/E ratio of 4.7×. In the wake of earnings, is it a buy or sell? Find out in our free research report.
The Best Stocks for High-Quality Investors
Donald Trump’s victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs.
While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
